Decreased serum esRAGE level is associated with angiographically determined coronary plaque progression in diabetic patients
Wen Hui Peng,Lin Lu,Jian Hu,Xiao Xiang Yan,Qi Zhang,Rui Yan Zhang,Qiu Jin Chen,Wei Feng Shen
DOI: https://doi.org/10.1016/j.clinbiochem.2009.04.017
IF: 3.625
2009-01-01
Clinical Biochemistry
Abstract:Results Comparing to baseline, serum esRAGE level was significantly increased during follow-up in nondiabetic patients without plaque progression ( p = 0.014), unchanged in nondiabetic patients with plaque progression and diabetic patients without plaque progression, and decreased in diabetic patients with plaque progression ( p = 0.011). Moreover, change of esRAGE levels correlated with change of QCA measurements. Multivariable regression analyses revealed that high-density lipoprotein cholesterol (OR = 0.214, p = 0.037), hypertension (OR = 2.755, p = 0.011), high-sensitivity C-reactive protein (OR = 1.083, p < 0.001) and change of esRAGE (OR = 23.477, p < 0.001) were independent risk factors for plaque progression in diabetic patients. Conclusions This study demonstrated an association of decreased serum esRAGE level with coronary plaque progression in patients with diabetes. Abbreviations AGEs advanced glycation endproducts c-RAGE cleaved receptor for advanced glycation endproducts esRAGE endogenous secretory receptor for advanced glycation endproducts HDL-C high-density lipoprotein cholesterol hsCRP high-sensitivity C-reactive protein LDL-C low-density lipoprotein cholesterol MACE major adverse cardiac events MLD minimal lumen diameter PCI percutaneous coronary intervention QCA quantitative coronary angiography RAGE receptor for advanced glycation endproducts SD standard deviation sRAGE soluble receptor for advanced glycation endproducts T2DM type 2 diabetes mellitus Keywords C-reactive protein Diabetes mellitus Endogenous secretory receptor for advanced glycation endproducts Plaque progression Introduction Evolution of atherosclerosis is an insidious process over the course of a lifetime, in which plaque forms in coronary arteries. Coronary plaques may progress rapidly and become vulnerable under the influence of reinforced local vascular inflammation and matrix metallopeptidase activities. Unstable plaques consequently rupture, leading to lethal cardiac events [1] . Diabetes is associated with intensified vascular inflammation and oxidative stress, which accelerate the development of atherosclerotic lesions [2] . Diabetic patients have an increased incidence of cardiovascular events and less favorable outcomes after myocardial infarction or coronary interventions [3,4] . One important mechanism of diabetic vascular complications is that advanced glycation endproducts (AGEs) produced in hyperglycemic milieu exert adverse impact on vascular function, via receptor for advanced glycation endproducts (RAGE) [5,6] . Activation of RAGE-mediated pathways leads to impaired vascular homeostasis, enhanced inflammatory signalings and increased cellular oxidative stress [7] , jointly contributing to atherosclerotic lesion progression [8,9] . Interference of AGEs' engagement to their receptor was achieved by administration of soluble forms of the receptor (sRAGE), which resulted in attenuated progression of established atherosclerosis in animal models [8] . Total sRAGE is a pool of RAGE variants, mainly composed of endogenous secretory forms (esRAGE) lacking transmembrane domain of the receptor, and proteolytically cleaved RAGE (c-RAGE) shed into the bloodstream upon by metalloproteinase action [10–12] . Both esRAGE and c-RAGE function as a decoy for AGEs, thus protecting vessel tissue from AGEs-induced pathology and mitigating development of atherosclerotic lesions. Nevertheless, the results of serum sRAGE levels in diabetic patients with vascular and target organ complications have not been replicated. Recent studies suggested that sRAGE was increased in diabetic patients with coronary artery disease [13] , while Yamasaki et al. reported an association of low sRAGE levels with progression of carotid intima-media thickness in diabetes mellitus [14] . Other studies including ours consistently indicated that esRAGE level was reduced in diabetic patients with vascular complications compared with those without [13–19] . Thus, in this study, we hypothesized that decreased serum esRAGE level may be associated with coronary plaque progression in patients with type 2 diabetes mellitus (T2DM). Since previous studies revealed a relationship between elevated inflammatory cytokines and plaque progression [20,21] , we also hypothesized that higher C-reactive protein level was related to plaque progression and correlated inversely with esRAGE concentration. Methods Study population The study protocol was approved by hospital Ethics Committee. Following institutional review, written informed consent from the patients was waived, as there were no experimental interventions, and patient confidentiality was guaranteed by the study protocol. Study participants were recruited from Shanghai Rui Jin Hospital Percutaneous Coronary Intervention (PCI) Outcomes Program. Briefly, this program utilized clinical and angiographic information for various cardiovascular diseases to estimate risk-adjusted outcomes. Data on patient demographics, clinical and angiographic features, and in-hospital management were collected retrospectively, whereas clinical outcomes during long-term follow-up were identified prospectively. A total of 576 consecutive patients with coronary artery disease underwent drug-eluting stent based PCI between October 2004 and December 2005. Excluded from the study were patients with acute myocardial infarction (56 patients), severe heart failure with left ventricular ejection fraction < 30% (25 patients), renal failure requiring dialysis (4 patients), type 1 diabetes and serious life-threatening illnesses or inflammation (21 patients). For the purpose of this study, patients who died (8 patients) or had no knowledge of repeat angiography during follow-up (169 patients), and loss to follow-up (13 patients) were also excluded from analysis. Another 15 patients were not included in this study because of symptom-driven repeat intervention or acute myocardial infarction undergoing primary PCI within 6 months of initial examination. The remaining 265 patients formed the study population, who had at least 1 stenotic lesion (luminal diameter narrowing > 20%) located at non-PCI intervened vessels on baseline coronary angiograms and received follow-up angiography at one year. Biochemical assessments Blood samples were collected after overnight fasting and stored at − 80 °C. White blood cell count and serum levels of glucose and lipid profiles (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], lipoprotein (a), apoprotein A and B, and triglycerides) were measured (HITACHI 912 Analyser, Roche Diagnostics, Germany). High sensitive C-reactive protein (hsCRP) (Biocheck Laboratories, USA) and esRAGE (Phoenix Biotech Co, LTD, USA) were determined by enzyme-linked immunosorbent assay (ELISA). esRAGE ELISA kit specifically measures endogenous secretory RAGE, but not c-RAGE, as detailed in protocol provided by the manufacturer. The linear range of the measurement for esRAGE and hsCRP were 0.05–3.2 ng/mL and 0.62–119.3 mg/L, respectively, and interassay coefficient of variation for esRAGE and hsCRP were < 10% and < 7.5%, respectively. Changes of biochemical measurements were defined as baseline measurement minus follow-up measurement. Coronary angiography and quantitative analysis Coronary arteriography and interventional procedures were performed by standard Judkins techniques or through radial approach [22] . Intracoronary injection of nitroglycerin (100 μg) was routinely made to avoid artery spasm. Coronary angiograms recorded at identical projections during initial and follow-up studies were used for quantitative coronary analyses (QCA, Centricity Cardiology CA 1000. v1.0, USA). All imaging analyses were performed by 2 experienced interventional cardiologists, who were blind to patients' clinical data. Severity of coronary atherosclerosis was defined according to number of coronary vessels with significant stenosis (angiographic luminal stenosis > 50%) as one-, two-, or three-vessel disease. For lesion analysis, end-diastolic frames from both baseline and follow-up angiograms were selected with identical angulations that best showed the stenosis at its most severe degree with minimal foreshortening and branch overlap. Matching arterial segments were defined from the images acquired on the basis of the anatomic location of proximal and distal side branches. The coronary artery segments analyzed included all those plaques with a reference diameter ≥ 1.5 mm and a stenosis ≥ 20% at baseline and those with new lesions at follow-up in non-PCI artery. All coronary arteries intervened with PCI were excluded to avoid inclusion of post-PCI neointimal hyperplasia or restenosis. Using the outer diameter of the contrast-filled catheter as the calibration, the minimal lumen diameter (MLD) in diastole was measured from multiple projection; the results from the single “worst” view were recorded. The reference segment diameter was averaged from user-defined, 5-mm-long, angiographically normal segments proximal and distal to the lesion but between any major side branches. Atherosclerotic plaque progression was defined as ≥ 1 lesion with decreased MLD ≥ 0.4 mm from baseline to follow-up angiography, a change representing approximately twice the SD for repeat measurements for lesions [23] . A new coronary lesion was defined as a stenosis that was not apparent on the initial angiogram or was < 20% in diameter stenosis but that narrowed by ≥ 0.4 mm in MLD at the follow-up angiogram [24] . Coronary artery score was calculated from per-patient average of the MLD of all the measured segments in observed coronary artery, and cumulative coronary obstruction was the sum of all percent diameter stenoses in standard index unit (50% = 0.50) [25] . Change of QCA measurements was defined as baseline QCA measurement minus follow-up measurement. Follow-up All patients were followed up in a special outpatient clinic or by telephone conversation with patients or their family members every 3 months after initial angiography. During follow-up, the emphasis was on symptoms and signs related to major adverse cardiac events (MACE), such as chest pain, unexplained dyspnea and mental disorder. MACE included non-fatal myocardial infarction and revascularization (repeat PCI or coronary artery bypass grafting). Myocardial infarction was defined according to the criteria of American Heart Association/American College of Cardiology. In order to guarantee rigorous data quality, all MACE were reviewed by 2 experienced interventional cardiologists. The choice of repeat PCI or coronary artery bypass grafting was at physician's discretion. Statistical analysis Continuous variables were expressed as mean ± SD, and categorical variables were presented as frequencies. Normal distribution was evaluated with Kolmogorov–Smirnov test. Logarithmic transformation was performed on the continuous variables of non-normal distribution before statistical calculations that requested normal distribution. Comparisons between groups were made using unpaired t tests, ANOVA or a nonparametric Mann–Whitney U test, when appropriate. Comparisons between baseline and follow-up measurements were performed with paired t tests, and qualitative variables were compared using Chi-square test. Pearson's correlations were used to test the relationship between continuous variables (e.g., esRAGE) and change of QCA measurements. Multivariate logistic regression model was constructed to assess the independent determinants of plaque progression. A 2-sided probability level of ≤ 0.05 was considered significant. All analyses were done with SPSS for Windows 13.0 (SPSS Inc, Chicago, Illinois). Results Clinical characteristics There were 152 nondiabetic and 113 diabetic patients, and plaque progression occurred in 42 (27.6%) nondiabetic and 42 (37.2%) diabetic patients. Patients with plaque progression did not differ significantly from those without plaque progression with respect to age, gender, cigarette smoking, systolic blood pressure, follow-up time, and medical treatments, but hypertension was more prevalent and duration of diabetes was longer in patients with plaque progression than in those without ( Table 1 ). Angiographic features Both diabetic and nondiabetic patients with plaque progression had more marked changes in MLD, coronary artery score and cumulative coronary obstruction, compared to those without (all p < 0.001) ( Table 2 ). In nondiabetic patients, the number of patients with plaque progression occurred at left anterior descending artery, left circumflex artery and right coronary artery was 11 (26.2%), 15 (35.7%), and 16 (38.1%), respectively. Repeat PCI was performed in 5 patients (11.9%) because of plaque progression. In diabetic group, plaque progression developed at left anterior descending artery, left circumflex artery, and right coronary artery in 12 (28.6%), 9 (21.4%), and 20 (47.6%) patients, respectively. Ten patients required repeat PCI for plaque progression. New coronary lesions occurred in 5 nondiabetic and 8 diabetic patients ( p = 0.720). Biochemical measurements The changes of biochemical measurements over 1-year follow-up were displayed in Table 3 . Serum cholesterol and apoprotein B were significantly reduced in all diabetic and nondiabetic patients with or without plaque progression (all p < 0.05). Triglyceride and LDL-C levels were decreased in diabetic and nondiabetic patients, respectively (all p < 0.05). Serum HDL-C was lower (1.05 ± 0.27 mmol/L vs. 1.20 ± 0.28 mmol/L) but lipoprotein (a) was higher (0.29 ± 0.18 g/L vs. 0.23 ± 0.16 g/L) at baseline in nondiabetic patients with plaque progression than in those without. These measurements did not change obviously in nondiabetic patients at follow-up. Fast glucose and glycosylated hemoglobin A1c levels did not differ significantly at follow-up in diabetic patients with or without plaque progression. White blood cell and neutrophile counts were decreased in nondiabetic and diabetic patients without plaque progression during follow-up (all p < 0.05) ( Table 3 ). Serum hsCRP level HsCRP level was higher in patients with plaque progression than those without at baseline irrespective of the presence or absence of diabetes ( Fig. 1 ). During follow-up, although serum hsCRP level was significantly decreased in nondiabetic patients with (from 20.77 ± 12.67 mg/L to 7.95 ± 4.57 mg/L, p < 0.001) or without plaque progression (from 9.87 ± 7.06 mg/L to 7.02 ± 4.88 mg/L, p < 0.001) compared with baseline, it was still higher in those with plaque progression (7.92 ± 4.40 mg/L vs. 6.85 ± 4.76 mg/L, p = 0.040). For diabetic patients, hsCRP level was also significantly reduced in those with (18.52 ± 14.80 mg/L to 9.13 ± 4.82 mg/L, p < 0.05) and without plaque progression (12.87 ± 9.13 mg/L to 8.81 ± 5.78 mg/L, p < 0.01) compared with baseline, and the difference in hsCRP between diabetic patients with and without plaque progression at follow-up did not reach statistically significant level. Serum esRAGE level Serum esRAGE level was significantly lower in diabetic patients, compared with nondiabetic counterparts (0.31 ± 0.16 ng/mL vs. 0.37 ± 0.14 ng/mL, p = 0.003) ( Fig. 2 ). For nondiabetic patients, esRAGE level was increased in those without plaque progression (from 0.36 ± 0.14 ng/mL to 0.40 ± 0.13 ng/mL, p = 0.014) at follow-up, but was unchanged in those with plaque progression. For diabetic patients, esRAGE level was unchanged in those with no plaque progression, but was decreased in those with plaque progression (from 0.32 ± 0.15 ng/mL to 0.25 ± 0.12 ng/mL, p = 0.011) at follow-up. This resulted in a marked difference in follow-up esRAGE level between patients with plaque progression and those without plaque progression in diabetic patients (0.25 ± 0.12 ng/mL vs. 0.34 ± 0.17 ng/mL, p = 0.002). Relation of serum esRAGE and hsCRP levels, and other risk factors to plaque progression Significant correlation was observed between change of esRAGE and changes of MLD, coronary artery score and cumulative coronary obstruction in nondiabetic ( r = 0.313, p < 0.001; r = 0.421, p < 0.001; r = 0.285, p < 0.01, respectively) and diabetic patients ( r = 0.231, p = 0.014; r = 0.362, p < 0.001; r = 0.355, p < 0.001, respectively). Multivariable logistics regression analysis, including conventional risk factors and measurements here performed ( Tables 1 and 3 ), revealed that HDL-C (OR = 0.214, p = 0.037), hypertension (OR = 2.755, p = 0.011), baseline hsCRP (OR = 1.083, p < 0.001), and change of esRAGE (OR = 23.477, p < 0.001) were risk factors for plaque progression ( Table 4 ). Predicted percentage correct of this regression model was 74.0%. Nagelkerke R 2 value was 0.279, suggesting the model explained 27.9% of the variation in the dependent variable. Hosmer–Lemeshow test was used to check the models' goodness of fit and the results demonstrated a good fit achieved (goodness of fit: Hosmer–Lemeshow χ 2 = 5.860, d.f. = 8, p = 0.663). Notably, although some factors (hypertension and duration of diabetes) were not equally distributed across groups at baseline ( Table 1 ), difference in esRAGE and hsCRP levels remained significant after adjusting potential confounders with a logistic regression model. Follow-up data There was no significant difference in rate of acute myocardial infarction between patients with plaque progression and those without in diabetic or nondiabetic groups after enrollment. However, the incidence of combined MACE during follow-up was significantly higher in diabetic patients with plaque progression than in those without (38.1% vs. 14.1%, p = 0.003) ( Table 1 ). Discussion This study demonstrated that decreased esRAGE and increased hsCRP levels were associated with coronary plaque progression over one-year period in patients with T2DM. Evidence suggested that esRAGE exerted an antagonizing effect on RAGE-mediated pro-atherogenic pathophysiology [26,27] . Recent studies showed that low circulatory esRAGE levels were associated with diabetes and diabetic vasculopathies including carotid intima-media thickness, a marker of atherosclerosis progression [15–18] . In this study, esRAGE level was significantly decreased in diabetic patients with plaque progression versus those without, and elevated in nondiabetic patients without plaque progression. These results indicate that a more aggravated atherogenic pathophysiology is implicated in patients with plaque progression reflected by their lower esRAGE levels. An increased esRAGE level heightened the protective effect on vessels, while a reduced esRAGE level was associated with accelerated atherosclerotic process. In addition, our results also showed that baseline hsCRP level was higher in patients with plaque progression than in those without for nondiabetes or diabetes, which supported the concept that an intensified inflammatory process played a central role in the acceleration of atherosclerosis, and “active” coronary event was associated with an increased level of acute-phase reactant and monocyte activation [28,29] . We observed an inverse relation between baseline esRAGE and hsCRP in diabetic patients, which was consistent with previous reports in healthy people [30] , but we did not find similar phenomenon in nondiabetic group. One explanation for this disparity was that almost all patients in this study received aggressive medical treatment, which altered serum levels of inflammatory cytokines [31] . On the other hand, esRAGE levels reflected the pathology of diabetic vasculopathies where RAGE expression was substantially up-regulated, leading to activation of inflammatory cytokine-producing pathways [32] . Thus, more associative effect appeared between esRAGE and hsCRP levels. Taken together, our findings supported a notion that intensified inflammatory process (reflected by elevated hsCRP level) and/or attenuated protective factors (partially reflected by reduced esRAGE level) were associated with plaque progression, particularly in diabetic patients. Thus, inhibition of inflammation and improvement of vascular protective factors were allegedly capable of mitigating atherosclerosis progression. Prevention of atherosclerosis progression and reduction of risk factors independently correlated with less clinical events in patients with coronary artery disease [33] . Putting it in perspective, medical therapy including statins and lifestyle changes may decrease inflammatory process and increase esRAGE level, especially for patients with diabetes. This study has several limitations. First, the sample size was small and the observation period was relatively short. Second, this study did not assess plaque progression or composition with intravascular ultrasound. Angiographic detection of atherosclerosis was confounded by a phenomenon known as the Glagov hypothesis or arterial remodeling [34,35] . As coronary plaques evolved, the external elastic membrane may gradually remodel in an outward direction. Accordingly, early alteration in atherosclerotic plaque may be not detectable by angiogram until the disease had advanced significantly. Third, treating patients to increase esRAGE and decrease inflammation with statins would be a way forward for patient health, and change in lifestyles secondary to getting the patients to eat healthily and exercise would correct many biochemical imbalances [17] . Finally, coronary compensatory remodeling was impaired in diabetic state [36,37] , thus, making judgments for diabetic lesion was more confident than nondiabetes in the present study. In summary, this study demonstrated an association of decreased serum esRAGE level with angiographically determined coronary plaque progression in patients with T2DM. Fully characterization of protective function of esRAGE for plaque progression in T2DM patients needed serial observation during long-term follow-up. References [1] R. Ross Atherosclerosis—an inflammatory disease N. Engl. J. Med. 340 1999 115 126 [2] P.J. Boyle Diabetes mellitus and macrovascular disease: mechanisms and mediators Am. J. Med. 120 2007 S12 S17 [3] M. Kosuge K. Kimura S. Kojima Effects of glucose abnormalities on in-hospital outcome after coronary intervention for acute myocardial infarction Circ. J. 69 2005 375 379 [4] R. Huxley F. Barzi M. Woodward Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies BMJ 332 2006 73 78 [5] A. Goldin J.A. Beckman A.M. Schmidt M.A. Creager Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 2006 597 605 [6] M. Neeper A.M. Schmidt J. Brett Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins J. Biol. Chem. 267 1992 14998 15004 [7] Y. Yamamoto S. Yamagishi H. Yonekura Roles of the AGE–RAGE system in vascular injury in diabetes Ann. N.Y. Acad. Sci. 902 2000 163 170 [8] L.G. Bucciarelli T. Wendt W. Qu RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice Circulation 106 2002 2827 2835 [9] J.M. Forbes L.T. Yee V. Thallas Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis Diabetes 53 2004 1813 1823 [10] G. Basta Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications Atherosclerosis 196 2008 9 21 [11] A. Raucci S. Cugusi A. Antonelli A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) FASEB J. 22 2008 3716 3727 [12] H. Yonekura Y. Yamamoto S. Sakurai Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury Biochem. J. 370 2003 1097 1109 [13] Yan XX, Lu L, Peng WH, et al. Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients. Atherosclerosis 2008 Dec 14. [Epub ahead of print] [14] Katakami N, Matsuhisa M, Kaneto H, et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 2008 Sep 2. [Epub ahead of print]. [15] N. Katakami M. Matsuhisa H. Kaneto Y. Yamasaki Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients Atherosclerosis 190 2007 22 23 [16] N. Katakami M. Matsuhisa H. Kaneto Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications Diabetes Care 28 2005 2716 2721 [17] H. Koyama T. Shoji H. Yokoyama Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis Arterioscler Thromb. Vasc. Biol. 25 2005 2587 2593 [18] S. Sakurai Y. Yamamoto H. Tamei Development of an ELISA for esRAGE and its application to type 1 diabetic patients Diabetes Res. Clin. Pract. 73 2006 158 165 [19] L. Lu L. Jin Pu Q.J. Chen Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients Clin. Chim. Acta 396 2008 33 37 [20] S.E. Nissen E.M. Tuzcu P. Schoenhagen Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N. Engl. J. Med. 352 2005 29 38 [21] D.V. Anand E. Lim D. Darko Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers J. Am. Coll. Cardiol. 50 2007 2218 2225 [22] L. Lu L.J. Pu X.W. Xu Association of serum levels of glycated albumin, C-reactive protein and tumor necrosis factor-alpha with the severity of coronary artery disease and renal impairment in patients with type 2 diabetes mellitus Clin. Biochem. 40 2007 810 816 [23] D. Waters J. Lesperance T.E. Craven G. Hudon L.D. Gillam Advantages and limitations of serial coronary arteriography for the assessment of progression and regression of coronary atherosclerosis. Implications for clinical trials Circulation 87 1993 II38 II47 [24] C. Berry P.L. L'Allier J. Gregoire Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression Circulation 115 2007 1851 1857 [25] D. Waters L. Higginson P. Gladstone Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial Circulation 89 1994 959 968 [26] I.H. Park S.I. Yeon J.H. Youn Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells Mol. Immunol. 40 2004 1203 1211 [27] A. Harashima Y. Yamamoto C. Cheng Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression Biochem. J. 396 2006 109 115 [28] S.E. Elias-Smale I. Kardys M. Oudkerk A. Hofman J.C. Witteman C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study Atherosclerosis 195 2007 e195 e202 [29] J. Danesh J.G. Wheeler G.M. Hirschfield C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease N. Engl. J. Med. 350 2004 1387 1397 [30] Y. Jang J.Y. Kim S.M. Kang Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans Metabolism 56 2007 199 205 [31] A. Radaelli C. Loardi M. Cazzaniga Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination Arterioscler Thromb. Vasc. Biol. 27 2007 2750 2755 [32] A.M. Schmidt S.D. Yan S.F. Yan D.M. Stern The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses J. Clin. Invest. 108 2001 949 955 [33] D. Waters T.E. Craven J. Lesperance Prognostic significance of progression of coronary atherosclerosis Circulation 87 1993 1067 1075 [34] S. Glagov E. Weisenberg C.K. Zarins R. Stankunavicius G.J. Kolettis Compensatory enlargement of human atherosclerotic coronary arteries N. Engl. J. Med. 316 1987 1371 1375 [35] P. Schoenhagen K.M. Ziada S.R. Kapadia T.D. Crowe S.E. Nissen E.M. Tuzcu Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study Circulation 101 2000 598 603 [36] S.J. Nicholls E.M. Tuzcu S. Kalidindi Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials J. Am. Coll. Cardiol. 52 2008 255 262 [37] P. Jimenez-Quevedo N. Suzuki C. Corros Vessel shrinkage as a sign of atherosclerosis progression in type 2 diabetes: a serial intravascular ultrasound analysis Diabetes 58 2009 209 214